Skip to Content

Infectious Disease Specialist discusses COVID treatments

Remaining Ad Time Ad - 00:00

LA CROSSE, Wis. (WXOW) - An infectious disease specialist spoke to the media on Friday about treatments for patients with COVID-19.

Dr. Raymund Razonable is Mayo Clinic Health System's Principal Investigator on a clinical trial involving Regeneron's Antibody Study.

He spoke about what the medical community is looking at when treating COVID-19 patients.

Razonable said those patients who receive Remedesivir recover in 10 days than 15 days to those who did not receive the drug.

He said the treatment Dexamethasone is used for COVID patients who are in mechanical ventilators, and that clinical studies show improvement in survival. COVID-19 patients not on a ventilator who use this drug showed it could be harmful he countered.

Razonable said Remdesivir is only for emergency use and that this drug is not FDA approved like Dexamethasone.

The President received several drugs to treat his COVID-19 symptoms after his diagnosis. Among them is the drug Remedesivir. The President also received Dexamethasone. It is too early to tell whether the combination is effective according to Dr. Razonable.

"Is it a cure, no, not yet," he said. "We cannot make that definitive conclusion at this time because this is currently undergoing randomized controlled clinical trials. Only when this trial is completed will we know if it is going to be effective or not."

There is currently a clinical trial of antibody therapy created by Regeneron, another option to help fight COVID-19. The company said early studies showed that the therapy "reduced viral load and associated symptoms in infected COVID-19 patients" according to the company's chief scientific officer. It also was showing promise in people whose immune response might be challenged.

Razonable said the clinical trials show the drug hydroxychloroquine is not effective in the treatment of COVID-19.

Convalescent plasma is another medical option scientists have listed to help treat COVID.

WQOW contributed to this story.

Author Profile Photo

Lindsey Ford

Lindsey Ford is a multimedia journalist.

Skip to content